– The safety run-in for Stage 2 of Bio-Path Holdings’ mid-stage trial of prexigebersen (BP1001) in conjunction with frontline therapies decitabine and venetoclax for the treatment of acute myeloid leukemia was completed successfully (AML).
– The safety run-in of Stage 2 of the trial was comprised of six evaluable patients who were treated with the triple combination.
Bio Path Holdings Inc (BPTH) is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about BPTH. We will be studying the movement so you can make the best decision as an investor. The stock has moved upwards today by 11.05%. The high for today is 10.17 and today’s low is 7.82. This information is critical in deciding whether this investment is risky or not. We can see the stock is trending upwards, which means the volume of people buying this stock is greater than people selling it.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
As an investor, you can get an idea of where the stock is trending by the forecast. In this case, the high forecast for Bio Path Holdings Inc is $13.00 and the low forecast is $11.50. We can get a look into the future by looking at past trends. Looking at Bio Path Holdings Inc ‘s 5-year movement it seems it has fallen 98%. Overall, Bio Path Holdings Inc is in great shape going forward. They have a strong market cap of $55.27M and a very bright future ahead of them.